Blood test may unlock targeted cancer drug for more bladder cancer patients
NCT ID NCT06129084
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 15 times
Summary
This study looks at whether a blood test can better identify genetic changes in metastatic bladder cancer than the usual tumor tissue test. These changes determine if a patient can take the drug erdafitinib. Researchers will compare results from both tests in 260 patients to see if the blood test finds more eligible patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arthur J.E Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2, Canada
-
BC Cancer Agency
Vancouver, British Columbia, V5Z 4E6, Canada
-
CHU de Québec-Université Laval
Québec, Quebec, G1R 2J6, Canada
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
London Health Sciences Centre
London, Ontario, N6A 5W9, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6, Canada
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.